The Role of Galectin-3 in Retinal Degeneration and Other Ocular Diseases: A Potential Novel Biomarker and Therapeutic Target
Abstract
:1. Introduction
2. Background of Galectins and Galectin-3
2.1. The Structure and Functions of the Galectin Family
2.2. The Unique Member of Galectins—Galectin-3
3. The Cell and Molecular Mechanisms of Gal3 in Diseases
3.1. Promoting Apoptosis
3.2. Promoting Inflammation
3.3. Promoting Fibrosis
3.4. Promoting Adhesion
3.5. Promoting Angiogenesis
4. The Regulation of Gal3 on Various Kinds of Retinal Cells
4.1. Gal3 and Microglia
4.2. Gal3 and Macrophage
4.3. Gal3 and RPE Cells
4.4. Gal3 and Endothelial Cells
4.5. Gal3 and Müller Cells
5. The Role of Gal3 in Retinal Diseases
5.1. Retinal Degenerative Disease
5.2. Age-Related Macular Degeneration
5.3. Glaucoma
5.4. Diabetic Retinopathy
6. The Potential Application of Gal3 in Clinical Practice
6.1. Gal3 Serving as a Biomarker in Diseases
6.2. The Inhibitors of Gal3 in the Clinical Trials
6.3. Gal3 as a Potential Target in Ocular Disease
7. Conclusions and Perspectives
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Campochiaro, P.A. Molecular pathogenesis of retinal and choroidal vascular diseases. Prog. Retin. Eye Res. 2015, 49, 67–81. [Google Scholar] [CrossRef]
- Davidson, P.J.; Davis, M.J.; Patterson, R.J.; Ripoche, M.A.; Poirier, F.; Wang, J.L. Shuttling of galectin-3 between the nucleus and cytoplasm. Glycobiology 2002, 12, 329–337. [Google Scholar] [CrossRef]
- Dong, R.; Zhang, M.; Hu, Q.; Zheng, S.; Soh, A.; Zheng, Y.; Yuan, H. Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review). Int. J. Mol. Med. 2018, 41, 599–614. [Google Scholar] [CrossRef] [PubMed]
- Bauer, P.M.; Zalis, M.C.; Abdshill, H.; Deierborg, T.; Johansson, F.; Englund-Johansson, U. Inflamed In Vitro Retina: Cytotoxic Neuroinflammation and Galectin-3 Expression. PLoS ONE 2016, 11, e0161723. [Google Scholar] [CrossRef]
- Tabel, M.; Wolf, A.; Szczepan, M.; Xu, H.; Jägle, H.; Moehle, C.; Chen, M.; Langmann, T. Genetic targeting or pharmacological inhibition of galectin-3 dampens microglia reactivity and delays retinal degeneration. J. Neuroinflammation 2022, 19, 229. [Google Scholar] [CrossRef] [PubMed]
- Tymińska, A.; Kapłon-Cieślicka, A.; Ozierański, K.; Budnik, M.; Wancerz, A.; Sypień, P.; Peller, M.; Maksym, J.; Balsam, P.; Opolski, G.; et al. Association of galectin-3 and soluble ST2 with in-hospital and 1-year outcomes in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Pol. Arch. Intern. Med. 2019, 129, 770–780. [Google Scholar] [CrossRef] [PubMed]
- van der Velde, A.R.; Lexis, C.P.; Meijers, W.C.; van der Horst, I.C.; Lipsic, E.; Dokter, M.M.; van Veldhuisen, D.J.; van der Harst, P.; de Boer, R.A. Galectin-3 and sST2 in prediction of left ventricular ejection fraction after myocardial infarction. Clin. Chim. Acta 2016, 452, 50–57. [Google Scholar] [CrossRef]
- Zhang, J.; Jiang, C.; Ruan, L.; Huang, X. Associations of cytokine concentrations in aqueous humour with retinal vascular abnormalities and exudation in Coats’ disease. Acta Ophthalmol. 2019, 97, 319–324. [Google Scholar] [CrossRef] [PubMed]
- de Boer, R.A.; Yu, L.; van Veldhuisen, D.J. Galectin-3 in cardiac remodeling and heart failure. Curr. Heart Fail. Rep. 2010, 7, 1–8. [Google Scholar] [CrossRef] [PubMed]
- Perea, R.J.; Morales-Ruiz, M.; Ortiz-Perez, J.T.; Bosch, X.; Andreu, D.; Borras, R.; Acosta, J.; Penela, D.; Prat-González, S.; de Caralt, T.M.; et al. Utility of galectin-3 in predicting post-infarct remodeling after acute myocardial infarction based on extracellular volume fraction mapping. Int. J. Cardiol. 2016, 223, 458–464. [Google Scholar] [CrossRef]
- Rabinovich, G.A. Galectins: An evolutionarily conserved family of animal lectins with multifunctional properties; a trip from the gene to clinical therapy. Cell Death Differ. 1999, 6, 711–721. [Google Scholar] [CrossRef] [PubMed]
- Rabinovich, G.A.; Baum, L.G.; Tinari, N.; Paganelli, R.; Natoli, C.; Liu, F.T.; Iacobelli, S. Galectins and their ligands: Amplifiers, silencers or tuners of the inflammatory response? Trends Immunol. 2002, 23, 313–320. [Google Scholar] [CrossRef] [PubMed]
- Caridi, B.; Doncheva, D.; Sivaprasad, S.; Turowski, P. Galectins in the Pathogenesis of Common Retinal Disease. Front. Pharmacol. 2021, 12, 687495. [Google Scholar] [CrossRef] [PubMed]
- Popa, S.J.; Stewart, S.E.; Moreau, K. Unconventional secretion of annexins and galectins. Semin. Cell Dev. Biol. 2018, 83, 42–50. [Google Scholar] [CrossRef]
- Johannes, L.; Jacob, R.; Leffler, H. Galectins at a glance. J. Cell Sci. 2018, 131, jcs208884. [Google Scholar] [CrossRef]
- Patterson, R.J.; Haudek, K.C.; Voss, P.G.; Wang, J.L. Examination of the role of galectins in pre-mRNA splicing. Methods Mol. Biol. 2015, 1207, 431–449. [Google Scholar] [CrossRef]
- Fred Brewer, C. Binding and cross-linking properties of galectins. Biochim. Biophys. Acta 2002, 1572, 255–262. [Google Scholar] [CrossRef]
- Brewer, C.F. Lectin cross-linking interactions with multivalent carbohydrates. Adv. Exp. Med. Biol. 2001, 491, 17–25. [Google Scholar] [CrossRef]
- Kasai, K.; Hirabayashi, J. Galectins: A family of animal lectins that decipher glycocodes. J. Biochem. 1996, 119, 1–8. [Google Scholar] [CrossRef]
- Patterson, R.J.; Wang, W.; Wang, J.L. Understanding the biochemical activities of galectin-1 and galectin-3 in the nucleus. Glycoconj. J. 2002, 19, 499–506. [Google Scholar] [CrossRef]
- Sörme, P.; Qian, Y.; Nyholm, P.G.; Leffler, H.; Nilsson, U.J. Low micromolar inhibitors of galectin-3 based on 3′-derivatization of N-acetyllactosamine. Chembiochem 2002, 3, 183–189. [Google Scholar] [CrossRef] [PubMed]
- Hovorková, M.; Červený, J.; Bumba, L.; Pelantová, H.; Cvačka, J.; Křen, V.; Renaudet, O.; Goyard, D.; Bojarová, P. Advanced high-affinity glycoconjugate ligands of galectins. Bioorg. Chem. 2023, 131, 106279. [Google Scholar] [CrossRef] [PubMed]
- Harjacek, M.; Diaz-Cano, S.; De Miguel, M.; Wolfe, H.; Maldonado, C.A.; Rabinovich, G.A. Expression of galectins-1 and -3 correlates with defective mononuclear cell apoptosis in patients with juvenile idiopathic arthritis. J. Rheumatol. 2001, 28, 1914–1922. [Google Scholar] [PubMed]
- Yang, R.Y.; Hsu, D.K.; Liu, F.T. Expression of galectin-3 modulates T-cell growth and apoptosis. Proc. Natl. Acad. Sci. USA 1996, 93, 6737–6742. [Google Scholar] [CrossRef]
- Peng, W.; Wang, H.Y.; Miyahara, Y.; Peng, G.; Wang, R.F. Tumor-associated galectin-3 modulates the function of tumor-reactive T cells. Cancer Res. 2008, 68, 7228–7236. [Google Scholar] [CrossRef] [PubMed]
- Yin, X.M.; Oltvai, Z.N.; Korsmeyer, S.J. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 1994, 369, 321–323. [Google Scholar] [CrossRef]
- Akahani, S.; Nangia-Makker, P.; Inohara, H.; Kim, H.R.; Raz, A. Galectin-3: A novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res. 1997, 57, 5272–5276. [Google Scholar]
- Yu, F.; Finley, R.L., Jr.; Raz, A.; Kim, H.R. Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation. J. Biol. Chem. 2002, 277, 15819–15827. [Google Scholar] [CrossRef]
- Thomas, L.; Pasquini, L.A. Galectin-3-Mediated Glial Crosstalk Drives Oligodendrocyte Differentiation and (Re)myelination. Front. Cell Neurosci. 2018, 12, 297. [Google Scholar] [CrossRef]
- Chaudhary, S.; Chaudhary, S.; Rawat, S.; Kulkarni, A.; Bilgrami, A.L.; Perveen, A.; Alghamdi, B.S.; Zughaibi, T.A.; Ashraf, G.M.; Alam, M.Z.; et al. Galectins-Potential Therapeutic Targets for Neurodegenerative Disorders. Int. J. Mol. Sci. 2022, 23, 1012. [Google Scholar] [CrossRef]
- Ge, M.M.; Chen, N.; Zhou, Y.Q.; Yang, H.; Tian, Y.K.; Ye, D.W. Galectin-3 in Microglia-Mediated Neuroinflammation: Implications for Central Nervous System Diseases. Curr. Neuropharmacol. 2022, 20, 2066–2080. [Google Scholar] [CrossRef] [PubMed]
- Venkatraman, A.; Hardas, S.; Patel, N.; Singh Bajaj, N.; Arora, G.; Arora, P. Galectin-3: An emerging biomarker in stroke and cerebrovascular diseases. Eur. J. Neurol. 2018, 25, 238–246. [Google Scholar] [CrossRef] [PubMed]
- Rahimian, R.; Béland, L.C.; Kriz, J. Galectin-3: Mediator of microglia responses in injured brain. Drug Discov. Today 2018, 23, 375–381. [Google Scholar] [CrossRef]
- Jeon, S.B.; Yoon, H.J.; Chang, C.Y.; Koh, H.S.; Jeon, S.H.; Park, E.J. Galectin-3 exerts cytokine-like regulatory actions through the JAK-STAT pathway. J. Immunol. 2010, 185, 7037–7046. [Google Scholar] [CrossRef]
- Burguillos, M.A.; Svensson, M.; Schulte, T.; Boza-Serrano, A.; Garcia-Quintanilla, A.; Kavanagh, E.; Santiago, M.; Viceconte, N.; Oliva-Martin, M.J.; Osman, A.M.; et al. Microglia-Secreted Galectin-3 Acts as a Toll-like Receptor 4 Ligand and Contributes to Microglial Activation. Cell Rep. 2015, 10, 1626–1638. [Google Scholar] [CrossRef] [PubMed]
- Lalancette-Hébert, M.; Swarup, V.; Beaulieu, J.M.; Bohacek, I.; Abdelhamid, E.; Weng, Y.C.; Sato, S.; Kriz, J. Galectin-3 is required for resident microglia activation and proliferation in response to ischemic injury. J. Neurosci. 2012, 32, 10383–10395. [Google Scholar] [CrossRef]
- Yip, P.K.; Carrillo-Jimenez, A.; King, P.; Vilalta, A.; Nomura, K.; Chau, C.C.; Egerton, A.M.; Liu, Z.H.; Shetty, A.J.; Tremoleda, J.L.; et al. Galectin-3 released in response to traumatic brain injury acts as an alarmin orchestrating brain immune response and promoting neurodegeneration. Sci. Rep. 2017, 7, 41689. [Google Scholar] [CrossRef]
- Pasquini, L.A.; Millet, V.; Hoyos, H.C.; Giannoni, J.P.; Croci, D.O.; Marder, M.; Liu, F.T.; Rabinovich, G.A.; Pasquini, J.M. Galectin-3 drives oligodendrocyte differentiation to control myelin integrity and function. Cell Death Differ. 2011, 18, 1746–1756. [Google Scholar] [CrossRef]
- Henderson, N.C.; Mackinnon, A.C.; Farnworth, S.L.; Poirier, F.; Russo, F.P.; Iredale, J.P.; Haslett, C.; Simpson, K.J.; Sethi, T. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc. Natl. Acad. Sci. USA 2006, 103, 5060–5065. [Google Scholar] [CrossRef] [PubMed]
- Fulton, D.J.R.; Li, X.; Bordan, Z.; Wang, Y.; Mahboubi, K.; Rudic, R.D.; Haigh, S.; Chen, F.; Barman, S.A. Galectin-3: A Harbinger of Reactive Oxygen Species, Fibrosis, and Inflammation in Pulmonary Arterial Hypertension. Antioxid. Redox Signal 2019, 31, 1053–1069. [Google Scholar] [CrossRef]
- Juniantito, V.; Izawa, T.; Yamamoto, E.; Murai, F.; Kuwamura, M.; Yamate, J. Heterogeneity of macrophage populations and expression of galectin-3 in cutaneous wound healing in rats. J. Comp. Pathol. 2011, 145, 378–389. [Google Scholar] [CrossRef]
- Henderson, N.C.; Mackinnon, A.C.; Farnworth, S.L.; Kipari, T.; Haslett, C.; Iredale, J.P.; Liu, F.T.; Hughes, J.; Sethi, T. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am. J. Pathol. 2008, 172, 288–298. [Google Scholar] [CrossRef] [PubMed]
- Morrow, D.A.; O’Donoghue, M.L. Galectin-3 in cardiovascular disease: A possible window into early myocardial fibrosis. J. Am. Coll. Cardiol. 2012, 60, 1257–1258. [Google Scholar] [CrossRef]
- Saccon, F.; Gatto, M.; Ghirardello, A.; Iaccarino, L.; Punzi, L.; Doria, A. Role of galectin-3 in autoimmune and non-autoimmune nephropathies. Autoimmun. Rev. 2017, 16, 34–47. [Google Scholar] [CrossRef] [PubMed]
- Dang, Z.; MacKinnon, A.; Marson, L.P.; Sethi, T. Tubular atrophy and interstitial fibrosis after renal transplantation is dependent on galectin-3. Transplantation 2012, 93, 477–484. [Google Scholar] [CrossRef]
- Mackinnon, A.C.; Gibbons, M.A.; Farnworth, S.L.; Leffler, H.; Nilsson, U.J.; Delaine, T.; Simpson, A.J.; Forbes, S.J.; Hirani, N.; Gauldie, J.; et al. Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3. Am. J. Respir Crit. Care Med. 2012, 185, 537–546. [Google Scholar] [CrossRef]
- Vergaro, G.; Prud’homme, M.; Fazal, L.; Merval, R.; Passino, C.; Emdin, M.; Samuel, J.L.; Cohen Solal, A.; Delcayre, C. Inhibition of Galectin-3 Pathway Prevents Isoproterenol-Induced Left Ventricular Dysfunction and Fibrosis in Mice. Hypertension 2016, 67, 606–612. [Google Scholar] [CrossRef]
- Mahendran, S.; Sethi, T. Treatments in idiopathic pulmonary fibrosis: Time for a more targeted approach? QJM Int. J. Med. 2012, 105, 929–934. [Google Scholar] [CrossRef] [PubMed]
- Chiang, C.K.; Hsu, S.P.; Wu, C.T.; Huang, J.W.; Cheng, H.T.; Chang, Y.W.; Hung, K.Y.; Wu, K.D.; Liu, S.H. Endoplasmic reticulum stress implicated in the development of renal fibrosis. Mol. Med. 2011, 17, 1295–1305. [Google Scholar] [CrossRef]
- Humphreys, B.D. Mechanisms of Renal Fibrosis. Annu. Rev. Physiol. 2018, 80, 309–326. [Google Scholar] [CrossRef]
- Taniguchi, T.; Asano, Y.; Akamata, K.; Noda, S.; Masui, Y.; Yamada, D.; Takahashi, T.; Ichimura, Y.; Toyama, T.; Tamaki, Z.; et al. Serum levels of galectin-3: Possible association with fibrosis, aberrant angiogenesis, and immune activation in patients with systemic sclerosis. J. Rheumatol. 2012, 39, 539–544. [Google Scholar] [CrossRef]
- Sharma, U.C.; Pokharel, S.; van Brakel, T.J.; van Berlo, J.H.; Cleutjens, J.P.; Schroen, B.; André, S.; Crijns, H.J.; Gabius, H.J.; Maessen, J.; et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004, 110, 3121–3128. [Google Scholar] [CrossRef]
- Calvier, L.; Miana, M.; Reboul, P.; Cachofeiro, V.; Martinez-Martinez, E.; de Boer, R.A.; Poirier, F.; Lacolley, P.; Zannad, F.; Rossignol, P.; et al. Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler. Thromb. Vasc. Biol. 2013, 33, 67–75. [Google Scholar] [CrossRef] [PubMed]
- Xin, M.; Dong, X.W.; Guo, X.L. Role of the interaction between galectin-3 and cell adhesion molecules in cancer metastasis. Biomed. Pharmacother. 2015, 69, 179–185. [Google Scholar] [CrossRef] [PubMed]
- Takenaka, Y.; Fukumori, T.; Raz, A. Galectin-3 and metastasis. Glycoconj. J. 2002, 19, 543–549. [Google Scholar] [CrossRef]
- Funasaka, T.; Raz, A.; Nangia-Makker, P. Galectin-3 in angiogenesis and metastasis. Glycobiology 2014, 24, 886–891. [Google Scholar] [CrossRef]
- Boscher, C.; Zheng, Y.Z.; Lakshminarayan, R.; Johannes, L.; Dennis, J.W.; Foster, L.J.; Nabi, I.R. Galectin-3 protein regulates mobility of N-cadherin and GM1 ganglioside at cell-cell junctions of mammary carcinoma cells. J. Biol. Chem. 2012, 287, 32940–32952. [Google Scholar] [CrossRef] [PubMed]
- de Oliveira, J.T.; de Matos, A.J.; Santos, A.L.; Pinto, R.; Gomes, J.; Hespanhol, V.; Chammas, R.; Manninen, A.; Bernardes, E.S.; Albuquerque Reis, C.; et al. Sialylation regulates galectin-3/ligand interplay during mammary tumour progression—A case of targeted uncloaking. Int. J. Dev. Biol. 2011, 55, 823–834. [Google Scholar] [CrossRef] [PubMed]
- Albelda, S.M. Role of integrins and other cell adhesion molecules in tumor progression and metastasis. Lab. Investig. 1993, 68, 4–17. [Google Scholar]
- Zhao, W.; Ajani, J.A.; Sushovan, G.; Ochi, N.; Hwang, R.; Hafley, M.; Johnson, R.L.; Bresalier, R.S.; Logsdon, C.D.; Zhang, Z.; et al. Galectin-3 Mediates Tumor Cell-Stroma Interactions by Activating Pancreatic Stellate Cells to Produce Cytokines via Integrin Signaling. Gastroenterology 2018, 154, 1524–1537.e1526. [Google Scholar] [CrossRef]
- Lee, S.H.; Khwaja Rehman, F.; Tyler, K.C.; Yu, B.; Zhang, Z.; Osuka, S.; Zerrouqi, A.; Kaluzova, M.; Hadjipanayis, C.G.; Cummings, R.D.; et al. A Chimeric Signal Peptide-Galectin-3 Conjugate Induces Glycosylation-Dependent Cancer Cell-Specific Apoptosis. Clin Cancer Res 2020, 26, 2711–2724. [Google Scholar] [CrossRef]
- Mourad-Zeidan, A.A.; Melnikova, V.O.; Wang, H.; Raz, A.; Bar-Eli, M. Expression profiling of Galectin-3-depleted melanoma cells reveals its major role in melanoma cell plasticity and vasculogenic mimicry. Am. J. Pathol. 2008, 173, 1839–1852. [Google Scholar] [CrossRef] [PubMed]
- Dudley, A.C.; Griffioen, A.W. Pathological angiogenesis: Mechanisms and therapeutic strategies. Angiogenesis 2023, 26, 313–347. [Google Scholar] [CrossRef]
- Shimura, T.; Takenaka, Y.; Tsutsumi, S.; Hogan, V.; Kikuchi, A.; Raz, A. Galectin-3, a novel binding partner of beta-catenin. Cancer Res. 2004, 64, 6363–6367. [Google Scholar] [CrossRef]
- Tsai, H.P.; Lin, C.J.; Lieu, A.S.; Chen, Y.T.; Tseng, T.T.; Kwan, A.L.; Loh, J.K. Galectin-3 Mediates Tumor Progression in Astrocytoma by Regulating Glycogen Synthase Kinase-3β Activity. Curr. Issues Mol. Biol. 2023, 45, 3591–3602. [Google Scholar] [CrossRef]
- Li, D.M.; Feng, Y.M. Signaling mechanism of cell adhesion molecules in breast cancer metastasis: Potential therapeutic targets. Breast Cancer Res. Treat 2011, 128, 7–21. [Google Scholar] [CrossRef] [PubMed]
- Jia, W.; Kidoya, H.; Yamakawa, D.; Naito, H.; Takakura, N. Galectin-3 Accelerates M2 Macrophage Infiltration and Angiogenesis in Tumors. Am. J. Pathol. 2013, 182, 1821–1831. [Google Scholar] [CrossRef]
- Zhang, Z.; Zheng, Y.; Wang, H.; Zhou, Y.; Tai, G. CD146 interacts with galectin-3 to mediate endothelial cell migration. FEBS Lett. 2018, 592, 1817–1828. [Google Scholar] [CrossRef]
- Fukushi, J.I.; Makagiansar, I.T.; Stallcup, W.B. NG2 proteoglycan promotes endothelial cell motility and angiogenesis via engagement of galectin-3 and alpha3beta1 integrin. Mol. Biol. Cell 2004, 15, 3580–3590. [Google Scholar] [CrossRef]
- Santos, S.N.D.; Sheldon, H.; Pereira, J.X.; Paluch, C.; Bernardes, E.S.J.O. Galectin-3 acts as an angiogenic switch to induce tumor angiogenesis via Jagged-1/Notch activation. Oncotarget 2017, 8, 49484. [Google Scholar] [CrossRef] [PubMed]
- Zhou, Z.Y.; Chang, T.F.; Lin, Z.B.; Jing, Y.T.; Wen, L.S.; Niu, Y.L.; Bai, Q.; Guo, C.M.; Sun, J.X.; Wang, Y.S.; et al. Microglial Galectin3 enhances endothelial metabolism and promotes pathological angiogenesis via Notch inhibition by competitively binding to Jag1. Cell Death Dis. 2023, 14, 380. [Google Scholar] [CrossRef] [PubMed]
- Markowska, A.I.; Liu, F.T.; Panjwani, N. Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenic response. J. Exp. Med. 2010, 207, 1981–1993. [Google Scholar] [CrossRef]
- Li, Y.; Chen, X.; Zeng, X.; Chen, S.; Yang, X.; Zhang, L. Galectin-3 mediates pulmonary vascular endothelial cell dynamics via TRPC1/4 under acute hypoxia. J. Biochem. Mol. Toxicol. 2020, 34, e22463. [Google Scholar] [CrossRef] [PubMed]
- Mehina, E.M.F.; Taylor, S.; Boghozian, R.; White, E.; Choi, S.E.; Cheema, M.S.; Korbelin, J.; Brown, C.E. Invasion of phagocytic Galectin 3 expressing macrophages in the diabetic brain disrupts vascular repair. Sci. Adv. 2021, 7, eabg2712. [Google Scholar] [CrossRef] [PubMed]
- Nayak, D.; Roth, T.L.; McGavern, D.B. Microglia development and function. Annu. Rev. Immunol. 2014, 32, 367–402. [Google Scholar] [CrossRef]
- Reichert, F.; Rotshenker, S. Galectin-3 (MAC-2) Controls Microglia Phenotype Whether Amoeboid and Phagocytic or Branched and Non-phagocytic by Regulating the Cytoskeleton. Front. Cell Neurosci. 2019, 13, 90. [Google Scholar] [CrossRef]
- García-Revilla, J.; Boza-Serrano, A.; Espinosa-Oliva, A.M.; Soto, M.S.; Deierborg, T.; Ruiz, R.; de Pablos, R.M.; Burguillos, M.A.; Venero, J.L. Galectin-3, a rising star in modulating microglia activation under conditions of neurodegeneration. Cell Death Dis. 2022, 13, 628. [Google Scholar] [CrossRef]
- Rahimian, R.; Lively, S.; Abdelhamid, E.; Lalancette-Hebert, M.; Schlichter, L.; Sato, S.; Kriz, J. Delayed Galectin-3-Mediated Reprogramming of Microglia After Stroke is Protective. Mol. Neurobiol. 2019, 56, 6371–6385. [Google Scholar] [CrossRef]
- Liu, Y.; Zhao, C.; Meng, J.; Li, N.; Xu, Z.; Liu, X.; Hou, S. Galectin-3 regulates microglial activation and promotes inflammation through TLR4/MyD88/NF-kB in experimental autoimmune uveitis. Clin. Immunol. 2022, 236, 108939. [Google Scholar] [CrossRef]
- Rahimian, R.; Béland, L.C.; Sato, S.; Kriz, J. Microglia-derived galectin-3 in neuroinflammation; a bittersweet ligand? Med. Res. Rev. 2021, 41, 2582–2589. [Google Scholar] [CrossRef]
- Rübsam, A.; Parikh, S.; Fort, P.E. Role of Inflammation in Diabetic Retinopathy. Int. J. Mol. Sci. 2018, 19, 942. [Google Scholar] [CrossRef]
- Shapouri-Moghaddam, A.; Mohammadian, S.; Vazini, H.; Taghadosi, M.; Esmaeili, S.A.; Mardani, F.; Seifi, B.; Mohammadi, A.; Afshari, J.T.; Sahebkar, A. Macrophage plasticity, polarization, and function in health and disease. J. Cell Physiol. 2018, 233, 6425–6440. [Google Scholar] [CrossRef] [PubMed]
- Lu, H.Y.; Shih, C.M.; Huang, C.Y.; Wu, A.T.H.; Cheng, T.M.; Mi, F.L.; Shih, C.C. Galectin-3 Modulates Macrophage Activation and Contributes Smooth Muscle Cells Apoptosis in Abdominal Aortic Aneurysm Pathogenesis. Int. J. Mol. Sci. 2020, 21, 8257. [Google Scholar] [CrossRef] [PubMed]
- Henderson, N.C.; Sethi, T. The regulation of inflammation by galectin-3. Immunol. Rev. 2009, 230, 160–171. [Google Scholar] [CrossRef]
- Di Gregoli, K.; Somerville, M.; Bianco, R.; Thomas, A.C.; Frankow, A.; Newby, A.C.; George, S.J.; Jackson, C.L.; Johnson, J.L. Galectin-3 Identifies a Subset of Macrophages with a Potential Beneficial Role in Atherosclerosis. Arterioscler. Thromb Vasc. Biol. 2020, 40, 1491–1509. [Google Scholar] [CrossRef] [PubMed]
- Ashery, U.; Yizhar, O.; Rotblat, B.; Elad-Sfadia, G.; Barkan, B.; Haklai, R.; Kloog, Y. Spatiotemporal organization of Ras signaling: Rasosomes and the galectin switch. Cell Mol. Neurobiol. 2006, 26, 471–495. [Google Scholar] [CrossRef]
- Shalom-Feuerstein, R.; Plowman, S.J.; Rotblat, B.; Ariotti, N.; Tian, T.; Hancock, J.F.; Kloog, Y. K-ras nanoclustering is subverted by overexpression of the scaffold protein galectin-3. Cancer Res. 2008, 68, 6608–6616. [Google Scholar] [CrossRef]
- Caberoy, N.B.; Alvarado, G.; Bigcas, J.L.; Li, W. Galectin-3 is a new MerTK-specific eat-me signal. J. Cell Physiol. 2012, 227, 401–407. [Google Scholar] [CrossRef]
- Yang, S.; Li, H.; Yao, H.; Zhang, Y.; Bao, H.; Wu, L.; Zhang, C.; Li, M.; Feng, L.; Zhang, J.; et al. Long noncoding RNA ERLR mediates epithelial-mesenchymal transition of retinal pigment epithelial cells and promotes experimental proliferative vitreoretinopathy. Cell Death Differ. 2021, 28, 2351–2366. [Google Scholar] [CrossRef]
- Priglinger, C.S.; Szober, C.M.; Priglinger, S.G.; Merl, J.; Euler, K.N.; Kernt, M.; Gondi, G.; Behler, J.; Geerlof, A.; Kampik, A.; et al. Galectin-3 induces clustering of CD147 and integrin-β1 transmembrane glycoprotein receptors on the RPE cell surface. PLoS ONE 2013, 8, e70011. [Google Scholar] [CrossRef]
- Alge-Priglinger, C.S.; Andre, S.; Schoeffl, H.; Kampik, A.; Strauss, R.W.; Kernt, M.; Gabius, H.J.; Priglinger, S.G. Negative regulation of RPE cell attachment by carbohydrate-dependent cell surface binding of galectin-3 and inhibition of the ERK-MAPK pathway. Biochimie 2011, 93, 477–488. [Google Scholar] [CrossRef] [PubMed]
- Andrade, F.E.C.; Correia-Silva, R.D.; Covre, J.L.; Lice, I.; Gomes, J.A.P.; Gil, C.D. Effects of galectin-3 protein on UVA-induced damage in retinal pigment epithelial cells. Photochem. Photobiol. Sci. 2023, 22, 21–32. [Google Scholar] [CrossRef] [PubMed]
- Ou, H.C.; Chou, W.C.; Hung, C.H.; Chu, P.M.; Hsieh, P.L.; Chan, S.H.; Tsai, K.L. Galectin-3 aggravates ox-LDL-induced endothelial dysfunction through LOX-1 mediated signaling pathway. Environ. Toxicol. 2019, 34, 825–835. [Google Scholar] [CrossRef]
- Reichenbach, A.; Bringmann, A. Glia of the human retina. Glia 2020, 68, 768–796. [Google Scholar] [CrossRef] [PubMed]
- Lew, D.S.; McGrath, M.J.; Finnemann, S.C. Galectin-3 Promotes Müller Glia Clearance Phagocytosis via MERTK and Reduces Harmful Müller Glia Activation in Inherited and Induced Retinal Degeneration. Front. Cell Neurosci. 2022, 16, 878260. [Google Scholar] [CrossRef]
- Bringmann, A.; Pannicke, T.; Grosche, J.; Francke, M.; Wiedemann, P.; Skatchkov, S.N.; Osborne, N.N.; Reichenbach, A. Müller cells in the healthy and diseased retina. Prog. Retin Eye Res. 2006, 25, 397–424. [Google Scholar] [CrossRef]
- Wang, M.; Ma, W.; Zhao, L.; Fariss, R.N.; Wong, W.T. Adaptive Müller cell responses to microglial activation mediate neuroprotection and coordinate inflammation in the retina. J. Neuroinflammation 2011, 8, 173. [Google Scholar] [CrossRef] [PubMed]
- Yan, Y.P.; Lang, B.T.; Vemuganti, R.; Dempsey, R.J. Galectin-3 mediates post-ischemic tissue remodeling. Brain Res. 2009, 1288, 116–124. [Google Scholar] [CrossRef]
- Boza-Serrano, A.; Reyes, J.F.; Rey, N.L.; Leffler, H.; Bousset, L.; Nilsson, U.; Brundin, P.; Venero, J.L.; Burguillos, M.A.; Deierborg, T. The role of Galectin-3 in α-synuclein-induced microglial activation. Acta Neuropathol. Commun. 2014, 2, 156. [Google Scholar] [CrossRef]
- Uehara, F.; Ohba, N.; Ozawa, M. Isolation and characterization of galectins in the mammalian retina. Investig. Ophthalmol. Vis. Sci. 2001, 42, 2164–2172. [Google Scholar]
- Canning, P.; Glenn, J.V.; Hsu, D.K.; Liu, F.T.; Gardiner, T.A.; Stitt, A.W. Inhibition of advanced glycation and absence of galectin-3 prevent blood-retinal barrier dysfunction during short-term diabetes. Exp. Diabetes Res. 2007, 2007, 51837. [Google Scholar] [CrossRef]
- Yang, Z.; Zhang, N.; Shen, H.; Lin, C.; Lin, L.; Yuan, B. Microglial activation with reduction in autophagy limits white matter lesions and improves cognitive defects during cerebral hypoperfusion. Curr. Neurovasc. Res. 2014, 11, 223–229. [Google Scholar] [CrossRef] [PubMed]
- Yamamoto, H.; Schmidt-Kastner, R.; Hamasaki, D.I.; Yamamoto, H.; Parel, J.M. Complex neurodegeneration in retina following moderate ischemia induced by bilateral common carotid artery occlusion in Wistar rats. Exp. Eye Res. 2006, 82, 767–779. [Google Scholar] [CrossRef]
- Block, F.; Schwarz, M.; Sontag, K.H. Retinal ischemia induced by occlusion of both common carotid arteries in rats as demonstrated by electroretinography. Neurosci. Lett. 1992, 144, 124–126. [Google Scholar] [CrossRef]
- Bouffette, S.; Botez, I.; De Ceuninck, F. Targeting galectin-3 in inflammatory and fibrotic diseases. Trends Pharmacol. Sci. 2023, 44, 519–531. [Google Scholar] [CrossRef] [PubMed]
- Amontree, M.; Deasy, S.; Turner, R.S.; Conant, K. Matrix disequilibrium in Alzheimer’s disease and conditions that increase Alzheimer’s disease risk. Front. Neurosci. 2023, 17, 1188065. [Google Scholar] [CrossRef] [PubMed]
- Gao, B.; Wang, S.; Li, J.; Han, N.; Ge, H.; Zhang, G.; Chang, M. HMGB1, angel or devil, in ischemic stroke. Brain Behav. 2023, 13, e2987. [Google Scholar] [CrossRef] [PubMed]
- Kim, J.B.; Sig Choi, J.; Yu, Y.M.; Nam, K.; Piao, C.S.; Kim, S.W.; Lee, M.H.; Han, P.L.; Park, J.S.; Lee, J.K. HMGB1, a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain. J. Neurosci. 2006, 26, 6413–6421. [Google Scholar] [CrossRef]
- Zhou, Z.; Jing, Y.; Niu, Y.; Chang, T.; Sun, J.; Guo, C.; Wang, Y.; Dou, G. Distinguished Functions of Microglia in the Two Stages of Oxygen-Induced Retinopathy: A Novel Target in the Treatment of Ischemic Retinopathy. Life 2022, 12, 1676. [Google Scholar] [CrossRef]
- Manouchehrian, O.; Arnér, K.; Deierborg, T.; Taylor, L. Who let the dogs out?: Detrimental role of Galectin-3 in hypoperfusion-induced retinal degeneration. J. Neuroinflammation 2015, 12, 92. [Google Scholar] [CrossRef]
- Bourne, R.R.A.; Jonas, J.B.; Bron, A.M.; Cicinelli, M.V.; Das, A.; Flaxman, S.R.; Friedman, D.S.; Keeffe, J.E.; Kempen, J.H.; Leasher, J.; et al. Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe in 2015: Magnitude, temporal trends and projections. Br. J. Ophthalmol. 2018, 102, 575–585. [Google Scholar] [CrossRef]
- An, E.; Lu, X.; Flippin, J.; Devaney, J.M.; Halligan, B.; Hoffman, E.P.; Strunnikova, N.; Csaky, K.; Hathout, Y. Secreted proteome profiling in human RPE cell cultures derived from donors with age related macular degeneration and age matched healthy donors. J. Proteome Res. 2006, 5, 2599–2610. [Google Scholar] [CrossRef] [PubMed]
- Yuan, X.; Gu, X.; Crabb, J.S.; Yue, X.; Shadrach, K.; Hollyfield, J.G.; Crabb, J.W. Quantitative proteomics: Comparison of the macular Bruch membrane/choroid complex from age-related macular degeneration and normal eyes. Mol. Cell Proteom. 2010, 9, 1031–1046. [Google Scholar] [CrossRef] [PubMed]
- Xue, J.; Gao, X.; Fu, C.; Cong, Z.; Jiang, H.; Wang, W.; Chen, T.; Wei, Q.; Qin, C. Regulation of galectin-3-induced apoptosis of Jurkat cells by both O-glycans and N-glycans on CD45. FEBS Lett. 2013, 587, 3986–3994. [Google Scholar] [CrossRef]
- Nakahara, S.; Oka, N.; Raz, A. On the role of galectin-3 in cancer apoptosis. Apoptosis 2005, 10, 267–275. [Google Scholar] [CrossRef] [PubMed]
- Fukumori, T.; Takenaka, Y.; Yoshii, T.; Kim, H.R.; Hogan, V.; Inohara, H.; Kagawa, S.; Raz, A. CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. Cancer Res. 2003, 63, 8302–8311. [Google Scholar]
- Matarrese, P.; Fusco, O.; Tinari, N.; Natoli, C.; Liu, F.T.; Semeraro, M.L.; Malorni, W.; Iacobelli, S. Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties. Int. J. Cancer 2000, 85, 545–554. [Google Scholar] [CrossRef]
- Newlaczyl, A.U.; Yu, L.G. Galectin-3--a jack-of-all-trades in cancer. Cancer Lett. 2011, 313, 123–128. [Google Scholar] [CrossRef]
- Al-Salam, S.; Kandhan, K.; Sudhadevi, M.; Yasin, J.; Tariq, S. Early Doxorubicin Myocardial Injury: Inflammatory, Oxidative Stress, and Apoptotic Role of Galectin-3. Int. J. Mol. Sci. 2022, 23, 2479. [Google Scholar] [CrossRef] [PubMed]
- Harazono, Y.; Nakajima, K.; Raz, A. Why anti-Bcl-2 clinical trials fail: A solution. Cancer Metastasis Rev. 2014, 33, 285–294. [Google Scholar] [CrossRef]
- Crespo-Garcia, S.; Tsuruda, P.R.; Dejda, A.; Ryan, R.D.; Fournier, F.; Chaney, S.Y.; Pilon, F.; Dogan, T.; Cagnone, G.; Patel, P.; et al. Pathological angiogenesis in retinopathy engages cellular senescence and is amenable to therapeutic elimination via BCL-xL inhibition. Cell Metab. 2021, 33, 818–832. [Google Scholar] [CrossRef] [PubMed]
- Tham, Y.C.; Li, X.; Wong, T.Y.; Quigley, H.A.; Aung, T.; Cheng, C.Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-analysis. Ophthalmology 2014, 121, 2081–2090. [Google Scholar] [CrossRef]
- Williams, P.A.; Marsh-Armstrong, N.; Howell, G.R. Neuroinflammation in glaucoma: A new opportunity. Exp. Eye Res. 2017, 157, 20–27. [Google Scholar] [CrossRef]
- Ahmad, I.; Subramani, M. Microglia: Friends or Foes in Glaucoma? A Developmental Perspective. Stem. Cells Transl. Med. 2022, 11, 1210–1218. [Google Scholar] [CrossRef] [PubMed]
- Kumar, S.; Akopian, A.; Bloomfield, S.A. Neuroprotection of Retinal Ganglion Cells Suppresses Microglia Activation in a Mouse Model of Glaucoma. Investig. Ophthalmol. Vis. Sci. 2023, 64, 24. [Google Scholar] [CrossRef]
- Butovsky, O.; Weiner, H.L. Microglial signatures and their role in health and disease. Nat. Rev. Neurosci. 2018, 19, 622–635. [Google Scholar] [CrossRef] [PubMed]
- Pitts, K.M.; Neeson, C.E.; Hall, N.E.; Lin, J.B.; Falah, H.K.; Wang, S.L.; Lo, K.T.; Song, C.E.; Margeta, M.A.; Solá-Del Valle, D.A. Neurodegeneration Markers Galectin-3 and Apolipoprotein E Are Elevated in the Aqueous Humor of Eyes with Glaucoma. Transl. Vis. Sci. Technol. 2022, 11, 1. [Google Scholar] [CrossRef]
- Margeta, M.A.; Yin, Z.; Madore, C.; Pitts, K.M.; Letcher, S.M.; Tang, J.; Jiang, S.; Gauthier, C.D.; Silveira, S.R.; Schroeder, C.M.; et al. Apolipoprotein E4 impairs the response of neurodegenerative retinal microglia and prevents neuronal loss in glaucoma. Immunity 2022, 55, 1627–1644.e1627. [Google Scholar] [CrossRef]
- Braunger, B.M.; Fuchshofer, R.; Tamm, E.R. The aqueous humor outflow pathways in glaucoma: A unifying concept of disease mechanisms and causative treatment. Eur. J. Pharm. Biopharm. 2015, 95, 173–181. [Google Scholar] [CrossRef]
- Argüeso, P.; Panjwani, N. Focus on molecules: Galectin-3. Exp. Eye Res. 2011, 92, 2–3. [Google Scholar] [CrossRef]
- Davis, C.H.; Kim, K.Y.; Bushong, E.A.; Mills, E.A.; Boassa, D.; Shih, T.; Kinebuchi, M.; Phan, S.; Zhou, Y.; Bihlmeyer, N.A.; et al. Transcellular degradation of axonal mitochondria. Proc. Natl. Acad. Sci. USA 2014, 111, 9633–9638. [Google Scholar] [CrossRef]
- Fujii, A.; Shearer, T.R.; Azuma, M. Galectin-3 enhances extracellular matrix associations and wound healing in monkey corneal epithelium. Exp. Eye Res. 2015, 137, 71–78. [Google Scholar] [CrossRef] [PubMed]
- Diskin, S.; Cao, Z.; Leffler, H.; Panjwani, N. The role of integrin glycosylation in galectin-8-mediated trabecular meshwork cell adhesion and spreading. Glycobiology 2009, 19, 29–37. [Google Scholar] [CrossRef]
- Suzuki, O.; Abe, M.; Hashimoto, Y. Sialylation and glycosylation modulate cell adhesion and invasion to extracellular matrix in human malignant lymphoma: Dependency on integrin and the Rho GTPase family. Int. J. Oncol. 2015, 47, 2091–2099. [Google Scholar] [CrossRef]
- Fautsch, M.P.; Silva, A.O.; Johnson, D.H. Carbohydrate binding proteins galectin-1 and galectin-3 in human trabecular meshwork. Exp. Eye Res. 2003, 77, 11–16. [Google Scholar] [CrossRef]
- Belmares, R.; Raychaudhuri, U.; Maansson, S.; Clark, A.F. Histological investigation of human glaucomatous eyes: Extracellular fibrotic changes and galectin 3 expression in the trabecular meshwork and optic nerve head. Clin. Anat. 2018, 31, 1031–1049. [Google Scholar] [CrossRef] [PubMed]
- Wang, W.; Lo, A.C.Y. Diabetic Retinopathy: Pathophysiology and Treatments. Int. J. Mol. Sci. 2018, 19, 1816. [Google Scholar] [CrossRef] [PubMed]
- Stitt, A.W.; Rice, M.A.; Glenn, J.V.; Liu, F.T.; Gardiner, T.A.J.D. Impaired Retinal Angiogenesis in Diabetes: Role of Advanced Glycation End Products and Galectin-3. Diabetes 2005, 54, 785–794. [Google Scholar] [CrossRef]
- Zhou, B.; Lin, W.; Long, Y.; Yang, Y.; Zhang, H.; Wu, K.; Chu, Q. Notch signaling pathway: Architecture, disease, and therapeutics. Signal. Transduct Target Ther. 2022, 7, 95. [Google Scholar] [CrossRef]
- Li, P.; Liu, S.; Lu, M.; Bandyopadhyay, G.; Oh, D.; Imamura, T.; Johnson, A.M.F.; Sears, D.; Shen, Z.; Cui, B.; et al. Hematopoietic-Derived Galectin-3 Causes Cellular and Systemic Insulin Resistance. Cell 2016, 167, 973–984.e912. [Google Scholar] [CrossRef]
- Darrow, A.L.; Shohet, R.V. Galectin-3 deficiency exacerbates hyperglycemia and the endothelial response to diabetes. Cardiovasc. Diabetol. 2015, 14, 73. [Google Scholar] [CrossRef]
- Köktürk, U.; Püşüroğlu, H.; Somuncu, M.U.; Akgül, Ö.; Uygur, B.; Özyılmaz, S.; Işıksaçan, N.; Sürgit, Ö.; Yıldırım, A. Short and Long-Term Prognostic Significance of Galectin-3 in Patients with ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Angiology 2023, 74, 33197221149846. [Google Scholar] [CrossRef]
- Asleh, R.; Enriquez-Sarano, M.; Jaffe, A.S.; Manemann, S.M.; Weston, S.A.; Jiang, R.; Roger, V.L. Galectin-3 Levels and Outcomes After Myocardial Infarction: A Population-Based Study. J. Am. Coll. Cardiol. 2019, 73, 2286–2295. [Google Scholar] [CrossRef] [PubMed]
- Li, M.; Guo, K.; Huang, X.; Feng, L.; Yuan, Y.; Li, J.; Lao, Y.; Guo, Z. Association Between Serum Galectin-3 Levels and Coronary Stenosis Severity in Patients with Coronary Artery Disease. Front. Cardiovasc. Med. 2022, 9, 818162. [Google Scholar] [CrossRef] [PubMed]
- Suthahar, N.; Meijers, W.C.; Silljé, H.H.W.; Ho, J.E.; Liu, F.T.; de Boer, R.A. Galectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease: An Update. Theranostics 2018, 8, 593–609. [Google Scholar] [CrossRef]
- Li, S.; Yu, Y.; Koehn, C.D.; Zhang, Z.; Su, K. Galectins in the Pathogenesis of Rheumatoid Arthritis. J. Clin. Cell Immunol. 2013, 4, 1000164. [Google Scholar] [CrossRef] [PubMed]
- Nielsen, M.A.; Juul-Madsen, K.; Stegmayr, J.; Gao, C.; Mehta, A.Y.; Greisen, S.R.; Kragstrup, T.W.; Hvid, M.; Vorup-Jensen, T.; Cummings, R.D.; et al. Galectin-3 Decreases 4-1BBL Bioactivity by Crosslinking Soluble and Membrane Expressed 4-1BB. Front. Immunol. 2022, 13, 915890. [Google Scholar] [CrossRef]
- Xie, Q.; Ni, M.; Wang, S.C. Galectin-3, A Potential Therapeutic Target for Rheumatoid Arthritis? Scand J. Immunol. 2018, 87, 108. [Google Scholar] [CrossRef]
- Neidhart, M.; Zaucke, F.; von Knoch, R.; Jüngel, A.; Michel, B.A.; Gay, R.E.; Gay, S. Galectin-3 is induced in rheumatoid arthritis synovial fibroblasts after adhesion to cartilage oligomeric matrix protein. Ann. Rheum. Dis. 2005, 64, 419–424. [Google Scholar] [CrossRef] [PubMed]
- Wang, C.R.; Shiau, A.L.; Chen, S.Y.; Cheng, Z.S.; Li, Y.T.; Lee, C.H.; Yo, Y.T.; Lo, C.W.; Lin, Y.S.; Juan, H.Y.; et al. Intra-articular lentivirus-mediated delivery of galectin-3 shRNA and galectin-1 gene ameliorates collagen-induced arthritis. Gene Ther. 2010, 17, 1225–1233. [Google Scholar] [CrossRef] [PubMed]
- Sciacchitano, S.; Lavra, L.; Morgante, A.; Ulivieri, A.; Magi, F.; De Francesco, G.P.; Bellotti, C.; Salehi, L.B.; Ricci, A. Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z. Int. J. Mol. Sci. 2018, 19, 379. [Google Scholar] [CrossRef] [PubMed]
- Caserta, D.; Di Benedetto, L.; Bordi, G.; D’Ambrosio, A.; Moscarini, M. Levels of Galectin-3 and Stimulation Expressed Gene 2 in the peritoneal fluid of women with endometriosis: A pilot study. Gynecol. Endocrinol. 2014, 30, 877–880. [Google Scholar] [CrossRef]
- García-Revilla, J.; Boza-Serrano, A.; Jin, Y.; Vadukul, D.M.; Soldán-Hidalgo, J.; Camprubí-Ferrer, L.; García-Cruzado, M.; Martinsson, I.; Klementieva, O.; Ruiz, R.; et al. Galectin-3 shapes toxic alpha-synuclein strains in Parkinson’s disease. Acta Neuropathol. 2023, 146, 51–75. [Google Scholar] [CrossRef] [PubMed]
- Ramírez Hernández, E.; Alanis Olvera, B.; Carmona González, D.; Guerrero Marín, O.; Pantoja Mercado, D.; Valencia Gil, L.; Hernández-Zimbrón, L.F.; Sánchez Salgado, J.L.; Limón, I.D.; Zenteno, E. Neuroinflammation and galectins: A key relationship in neurodegenerative diseases. Glycoconj. J. 2022, 39, 685–699. [Google Scholar] [CrossRef]
- Mattos, R.M.; Machado, D.E.; Perini, J.A.; Alessandra-Perini, J.; Meireles da Costa, N.O.; Wiecikowski, A.; Cabral, K.; Takiya, C.M.; Carvalho, R.S.; Nasciutti, L.E. Galectin-3 plays an important role in endometriosis development and is a target to endometriosis treatment. Mol. Cell Endocrinol. 2019, 486, 1–10. [Google Scholar] [CrossRef] [PubMed]
- Stojanovic, B.S.; Stojanovic, B.; Milovanovic, J.; Arsenijević, A.; Dimitrijevic Stojanovic, M.; Arsenijevic, N.; Milovanovic, M. The Pivotal Role of Galectin-3 in Viral Infection: A Multifaceted Player in Host-Pathogen Interactions. Int. J. Mol. Sci. 2023, 24, 9617. [Google Scholar] [CrossRef]
- Caniglia, J.L.; Guda, M.R.; Asuthkar, S.; Tsung, A.J.; Velpula, K.K. A potential role for Galectin-3 inhibitors in the treatment of COVID-19. PeerJ 2020, 8, e9392. [Google Scholar] [CrossRef]
- Caniglia, J.L.; Asuthkar, S.; Tsung, A.J.; Guda, M.R.; Velpula, K.K. Immunopathology of galectin-3: An increasingly promising target in COVID-19. F1000Research 2020, 9, 1078. [Google Scholar] [CrossRef]
- Machala, E.A.; McSharry, B.P.; Rouse, B.T.; Abendroth, A.; Slobedman, B. Gal power: The diverse roles of galectins in regulating viral infections. J. Gen. Virol. 2019, 100, 333–349. [Google Scholar] [CrossRef]
- Behnoush, A.H.; Khalaji, A.; Alemohammad, S.Y.; Kalantari, A.; Cannavo, A.; Dimitroff, C.J. Galectins can serve as biomarkers in COVID-19: A comprehensive systematic review and meta-analysis. Front. Immunol. 2023, 14, 1127247. [Google Scholar] [CrossRef]
- Garcia-Revilla, J.; Deierborg, T.; Venero, J.L.; Boza-Serrano, A. Hyperinflammation and Fibrosis in Severe COVID-19 Patients: Galectin-3, a Target Molecule to Consider. Front. Immunol. 2020, 11, 2069. [Google Scholar] [CrossRef]
- Hirani, N.; MacKinnon, A.C.; Nicol, L.; Ford, P.; Schambye, H.; Pedersen, A.; Nilsson, U.J.; Leffler, H.; Sethi, T.; Tantawi, S.; et al. Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis. Eur. Respir. J. 2021, 57, 2002559. [Google Scholar] [CrossRef]
- Zetterberg, F.R.; MacKinnon, A.; Brimert, T.; Gravelle, L.; Johnsson, R.E.; Kahl-Knutson, B.; Leffler, H.; Nilsson, U.J.; Pedersen, A.; Peterson, K.; et al. Discovery and Optimization of the First Highly Effective and Orally Available Galectin-3 Inhibitors for Treatment of Fibrotic Disease. J. Med. Chem. 2022, 65, 12626–12638. [Google Scholar] [CrossRef] [PubMed]
- Park, A.M.; Khadka, S.; Sato, F.; Omura, S.; Fujita, M.; Hsu, D.K.; Liu, F.T.; Tsunoda, I. Galectin-3 as a Therapeutic Target for NSAID-Induced Intestinal Ulcers. Front. Immunol. 2020, 11, 550366. [Google Scholar] [CrossRef] [PubMed]
- Gaughan, E.E.; Quinn, T.M.; Mills, A.; Bruce, A.M.; Antonelli, J.; MacKinnon, A.C.; Aslanis, V.; Li, F.; O’Connor, R.; Boz, C.; et al. An Inhaled Galectin-3 Inhibitor in COVID-19 Pneumonitis: A Phase Ib/IIa Randomized Controlled Clinical Trial (DEFINE). Am. J. Respir. Crit. Care Med. 2023, 207, 138–149. [Google Scholar] [CrossRef]
- Chalasani, N.; Abdelmalek, M.F.; Garcia-Tsao, G.; Vuppalanchi, R.; Alkhouri, N.; Rinella, M.; Noureddin, M.; Pyko, M.; Shiffman, M.; Sanyal, A.; et al. Effects of Belapectin, an Inhibitor of Galectin-3, in Patients with Nonalcoholic Steatohepatitis with Cirrhosis and Portal Hypertension. Gastroenterology 2020, 158, 1334–1345.e1335. [Google Scholar] [CrossRef] [PubMed]
- Machado, M.V.; Diehl, A.M. Liver renewal: Detecting misrepair and optimizing regeneration. Mayo Clin. Proc. 2014, 89, 120–130. [Google Scholar] [CrossRef]
- Curti, B.D.; Koguchi, Y.; Leidner, R.S.; Rolig, A.S.; Sturgill, E.R.; Sun, Z.; Wu, Y.; Rajamanickam, V.; Bernard, B.; Hilgart-Martiszus, I.; et al. Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor. J. Immunother. Cancer 2021, 9, e002371. [Google Scholar] [CrossRef]
- Ito, Y.; Usui-Ouchi, A.; Ebihara, N. Galectin-3, a damage-associated molecular pattern, in tears of patients with vernal keratoconjunctivitis. JPN J. Ophthalmol. 2023, 67, 431–439. [Google Scholar] [CrossRef]
- Baghban, R.; Farajnia, S.; Ghasemi, Y.; Hoseinpoor, R.; Safary, A.; Mortazavi, M.; Zarghami, N. Mutational Analysis of Ocriplasmin to Reduce Proteolytic and Autolytic Activity in Pichia pastoris. Biol. Proced Online 2020, 22, 25. [Google Scholar] [CrossRef]
- Stalmans, P.; Benz, M.S.; Gandorfer, A.; Kampik, A.; Girach, A.; Pakola, S.; Haller, J.A. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N. Engl. J. Med. 2012, 367, 606–615. [Google Scholar] [CrossRef] [PubMed]
- Velaga, S.B.; Nittala, M.G.; Ip, M.S.; Duchateau, L.; Sadda, S.R. Post hoc analysis of ellipsoid zone changes beyond the central subfield in symptomatic vitreomacular adhesion patients from the OASIS trial. BMJ Open Ophthalmol. 2021, 6, e000648. [Google Scholar] [CrossRef] [PubMed]
- Yuan, T.H.; Yue, Z.S.; Zhang, G.H.; Wang, L.; Dou, G.R. Beyond the Liver: Liver-Eye Communication in Clinical and Experimental Aspects. Front. Mol. Biosci. 2021, 8, 823277. [Google Scholar] [CrossRef] [PubMed]
Name | Disease | Clinical Trial |
---|---|---|
TD139 | idiopathic pulmonary fibrosis | NCT02257177 |
NCT03832946 | ||
GB0139 | COVID-19 | NCT04473053 |
GR-MD-02 | non-alcoholic steatohepatitis | NCT01899859 |
non-small cell lung cancer | NCT02117362 | |
NCT02575404 | ||
NCT04987996 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Zhou, Z.; Feng, Z.; Sun, X.; Wang, Y.; Dou, G. The Role of Galectin-3 in Retinal Degeneration and Other Ocular Diseases: A Potential Novel Biomarker and Therapeutic Target. Int. J. Mol. Sci. 2023, 24, 15516. https://doi.org/10.3390/ijms242115516
Zhou Z, Feng Z, Sun X, Wang Y, Dou G. The Role of Galectin-3 in Retinal Degeneration and Other Ocular Diseases: A Potential Novel Biomarker and Therapeutic Target. International Journal of Molecular Sciences. 2023; 24(21):15516. https://doi.org/10.3390/ijms242115516
Chicago/Turabian StyleZhou, Ziyi, Zhaochen Feng, Xiaojia Sun, Yusheng Wang, and Guorui Dou. 2023. "The Role of Galectin-3 in Retinal Degeneration and Other Ocular Diseases: A Potential Novel Biomarker and Therapeutic Target" International Journal of Molecular Sciences 24, no. 21: 15516. https://doi.org/10.3390/ijms242115516